Antonio Juretic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12004969/publications.pdf

Version: 2024-02-01

27 papers	1,075 citations	516710 16 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	835 citing authors

#	Article	IF	Citations
1	Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2022, 12, 941.	2.5	3
2	Clinical oncology module for the ESTRO core curriculum. Radiotherapy and Oncology, 2021, 156, 19-22.	0.6	9
3	Recommended ESTRO Core Curriculum for Radiation Oncology/Radiotherapy 4th edition. Radiotherapy and Oncology, 2019, 141, 1-4.	0.6	41
4	Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome â€“ Evaluation of awareness and implementation among Croatian oncologists. Clinical Nutrition ESPEN, 2019, 33, 202-206.	1.2	0
5	Giant desmoplastic cutaneous squamous cell carcinoma of the gluteal region. World Journal of Surgical Oncology, 2017, 15, 121.	1.9	2
6	The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2305-2317.	1.6	19
7	Clinical Significance of Immunohistochemical Expression of Cancer/Testis Tumor-associated Antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in Patients with Non-small Cell Lung Cancer. Tumori, 2014, 100, 60-68.	1.1	19
8	Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas. Acta Histochemica, 2014, 116, 740-746.	1.8	7
9	High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Medical Oncology, 2012, 29, 1586-1591.	2.5	24
10	Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study. Croatian Medical Journal, 2011, 52, 171-177.	0.7	16
11	Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer. Tumori, 2008, 94, 838-844.	1.1	21
12	Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Collegium Antropologicum, 2008, 32, 731-6.	0.2	21
13	Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori, 2008, 94, 838-44.	1.1	10
14	Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croatian Medical Journal, 2006, 47, 32-41.	0.7	33
15	Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncology, The, 2003, 4, 104-109.	10.7	93
16	Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma. Oncology, 2003, 64, 443-449.	1.9	33
17	Radiotherapy of stage IEA primary breast lymphoma: case report. Croatian Medical Journal, 2002, 43, 569-72.	0.7	2
18	Peptide-specific ctl in tumor-infiltrating lymphocytes from metastatic melanomas expressing mart-1/melan-a, gp100 and tyrosinase genes: A study in an unselected group of hla-a2.1-positive patients. International Journal of Cancer, 1995, 64, 309-315.	5.1	52

#	Article	IF	Citations
19	The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. International Journal of Cancer, 1994, 57, 612-619.	5.1	111
20	MAGE-1 gene product is a cytoplasmic protein. International Journal of Cancer, 1994, 59, 435-439.	5.1	54
21	Exogenous glutamine requirement is confined to late events of T cell activation. Journal of Cellular Biochemistry, 1993, 53, 343-351.	2.6	74
22	SV40 T antigen acts as a minor histocompatibility antigen of SV40 T antigen tolerant transgenic mice. Immunogenetics, 1989, 29, 366-370.	2.4	10
23	Cytolytic T cells activated by H-2-controlled E molecules cross-react with A molecules. Immunogenetics, 1982, 15, 519-527.	2.4	2
24	Lyt phenotypes of primary cytotoxic T cells generated across the A and E region of the H-2 complex. European Journal of Immunology, 1981, 11, 499-504.	2.9	45
25	Generation of cytotoxic T lymphocytes by the H-2-encoded E molecules. Immunogenetics, 1981, 14, 73-83.	2.4	11
26	Detection of CML determinants associated with Hâ€“2 controlled EÎ² and EÎ±chains. Nature, 1981, 289, 308-310.	27.8	27
27	The traditional and a new version of the mouse Hâ€“2 complex. Nature, 1981, 291, 455-460.	27.8	324